UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

04 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Read More Share:

Jan

21 Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Read More Share:

Jan

19 UCB to acquire Zogenix

Read More Share:

Jan

18 Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Read More Share:

Dec

16 Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Read More Share:

Dec

10 UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Read More Share:

Nov

19 Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Read More Share:

Nov

05 UCB Showcases Key Rheumatology Data at ACR Convergence 2021

Read More Share:

Oct

16 Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Read More Share:

Sep

29 New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Read More Share:

Categories

Archives

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Jan

19

UCB to acquire Zogenix

Jan

18

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Dec

16

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Nov

05

UCB Showcases Key Rheumatology Data at ACR Convergence 2021

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Choose Country

UCB in the U.S.

Patients

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Jan

19

UCB to acquire Zogenix

Jan

18

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Dec

16

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Nov

05

UCB Showcases Key Rheumatology Data at ACR Convergence 2021

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Disease Areas

Sustainability

Newsroom

Contact